首页> 外文期刊>Arthritis and Rheumatism >Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes
【24h】

Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes

机译:用anakinra治疗的新生儿多发性炎性疾病患者的持续应答和预防损害进展:一项确定三年和五年预后的队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective. Blocking interleukin-1 with anakinra in patients with the autoinflammatory syndrome neonatal-onset multisystem inflammatory disease (NOMID) reduces systemic and organ-specific inflammation. However, the impact of long-term treatment has not been established. This study was undertaken to evaluate the long-term effect of anakinra on clinical and laboratory outcomes and safety in patients with NOMID. Methods. We conducted a cohort study of 26 NOMID patients ages 0.80-42.17 years who were followed up at the NIH and treated with anakinra 1-5 mg/kg/day for at least 36 months. Disease activity was assessed using daily diaries, questionnaires, and C-reactive protein level. Central nervous system (CNS) inflammation, hearing, vision, and safety were evaluated. Results. Sustained improvements in diary scores, parent's/patient's and physician's global scores of disease activity, parent's/patient's pain scores, and inflammatory markers were observed (all P < 0.001 at 36 and 60 months). At 36 and 60 months, CNS inflammation was suppressed, with decreased cerebrospinal fluid white blood cell counts (P = 0.0026 and P = 0.0076, respectively), albumin levels, and opening pressures (P = 0.0012 and P < 0.001, respectively). Most patients showed stable or improved hearing. Cochlear enhancement on magnetic resonance imaging correlated with continued hearing loss. Visual acuity and peripheral vision were stable. Low optic nerve size correlated with poor visual field. Bony lesions progressed. Adverseevents other than viral infections were rare, and all patients continued to receive the medication. Conclusion. These findings indicate that anakinra provides sustained efficacy in the treatment of NOMID for up to 5 years, with the requirement of dose escalation. Damage progression in the CNS, ear, and eye, but not bone, is preventable. Anakinra is well tolerated overall.
机译:目的。在患有自发性炎症综合征新生儿多系统炎性疾病(NOMID)的患者中,用anakinra阻断白细胞介素-1可以减少全身性和器官特异性炎症。但是,长期治疗的影响尚未确定。这项研究旨在评估anakinra对NOMID患者的临床和实验室结果以及安全性的长期影响。方法。我们对26名0.80-42.17岁的NOMID患者进行了一项队列研究,这些患者在NIH接受了随访,并接受anakinra 1-5 mg / kg / day的治疗至少36个月。使用每日日记,问卷和C反应蛋白水平评估疾病活动。评估中枢神经系统(CNS)的炎症,听力,视力和安全性。结果。观察到日记评分,父母/患者和医师的疾病活动总体评分,父母/患者的疼痛评分和炎症标记的持续改善(在36和60个月时所有P <0.001)。在第36和60个月时,中枢神经系统炎症得到抑制,脑脊液白细胞计数(分别为P = 0.0026和P = 0.0076),白蛋白水平和开放压力(分别为P = 0.0012和P <0.001)减少。大多数患者表现出稳定或改善的听力。磁共振成像上的耳蜗增强与持续的听力损失有关。视力和周围视觉稳定。视神经大小低与视野差有关。骨性病变进展。除病毒感染外,很少发生不良事件,所有患者继续接受药物治疗。结论。这些发现表明,anakinra在NOMID的治疗中可提供长达5年的持续疗效,并且需要逐步提高剂量。可以预防中枢神经系统,耳朵和眼睛(而非骨骼)的损伤进展。 Anakinra的总体耐受性良好。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号